1. Home
  2. GLU vs ANIX Comparison

GLU vs ANIX Comparison

Compare GLU & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$19.49

Market Cap

119.8M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.56

Market Cap

108.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
ANIX
Founded
2004
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.8M
108.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GLU
ANIX
Price
$19.49
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
6.2K
282.9K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
12.82
EPS
0.62
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.11
$2.32
52 Week High
$21.69
$5.46

Technical Indicators

Market Signals
Indicator
GLU
ANIX
Relative Strength Index (RSI) 56.62 65.77
Support Level $19.32 $2.48
Resistance Level $20.17 $4.52
Average True Range (ATR) 0.22 0.28
MACD 0.03 0.04
Stochastic Oscillator 74.80 85.86

Price Performance

Historical Comparison
GLU
ANIX

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: